ProCE Banner Activity

Phase III GEM-CLARIDEX: Clarithromycin Plus Rd vs Rd Alone in Newly Diagnosed, Transplant-Ineligible Patients with Myeloma

Slideset Download
Conference Coverage
Results from phase III study suggest no significant PFS improvement from addition of clarithromycin to Rd in newly diagnosed, transplant-ineligible patients with myeloma.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company